MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Pfizer

Abrir

SetorSaúde

27.51 2.23

Visão Geral

Variação de preço das ações

24h

Atual

Mín

26.63

Máximo

27.56

Indicadores-chave

By Trading Economics

Rendimento

-45M

2.9B

Vendas

938M

15B

P/E

Médio do Setor

12.553

35.739

EPS

0.51

Rendimento de Dividendos

7.15

Margem de lucro

19.982

Funcionários

81,000

EBITDA

266M

5.3B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+4.85% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

7.15%

3.08%

Próximos Ganhos

4 de nov. de 2025

Próxima data de dividendos

1 de dez. de 2025

Próxima data de ex-dividendo

7 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.8B

136B

Abertura anterior

25.28

Fecho anterior

27.51

Sentimento de Notícias

By Acuity

46%

54%

140 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Pfizer Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de out. de 2025, 08:54 UTC

Grandes Movimentos do Mercado

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

30 de set. de 2025, 15:07 UTC

Grandes Movimentos do Mercado

Pfizer Shares Rise After WSJ Reports Company Will Lower Drug Costs

22 de set. de 2025, 14:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- 2nd Update

22 de set. de 2025, 11:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

22 de set. de 2025, 11:09 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion

22 de set. de 2025, 10:13 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

Metsera Shares Leap Premarket on Report of Takeover by Pfizer

22 de set. de 2025, 07:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer Nears $7.3 Billion Metsera Deal, FT Says, Citing Sources

5 de ago. de 2025, 11:34 UTC

Ganhos

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

22 de set. de 2025, 15:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer Jumps Back into the Weight-Loss Race With $4.9B Acquisition -- Barrons.com

22 de set. de 2025, 13:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

22 de set. de 2025, 11:26 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Fox, Coinbase, Metsera, Pfizer, Kenvue, Anywhere Real Estate, Premier, and More -- Barrons.com

22 de set. de 2025, 11:26 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- WSJ

22 de set. de 2025, 10:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer: Metsera Deal Adds Four Clinical-Stage Incretin, Amylin Programs to Pipeline >PFE MTSR

22 de set. de 2025, 10:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer: Metsera Deal Includes Contingent Value Rights Worth Up to Additional $22.50/Share >PFE MTSR

22 de set. de 2025, 10:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer: Metsera Deal Has Initial Enterprise Value of $4.9 Billion >PFE MTSR

22 de set. de 2025, 10:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer to Pay Initial $47.50/Share for Metsera >PFE MTSR

22 de set. de 2025, 10:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer to Acquire Metsera and Its Next-Generation Obesity Portfolio >PFE MTSR

22 de set. de 2025, 09:12 UTC

Ações em Alta

Stocks to Watch Monday: Nippon Steel, Porsche, Infosys, Metsera -- WSJ

5 de ago. de 2025, 20:44 UTC

Ganhos

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 de ago. de 2025, 18:20 UTC

Ganhos

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 de ago. de 2025, 18:17 UTC

Ganhos

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 de ago. de 2025, 16:04 UTC

Conversa de Mercado

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

5 de ago. de 2025, 15:25 UTC

Ganhos

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 de ago. de 2025, 13:56 UTC

Ganhos

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 de ago. de 2025, 11:43 UTC

Ganhos

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

5 de ago. de 2025, 11:27 UTC

Ganhos

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 de ago. de 2025, 10:57 UTC

Ganhos

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

5 de ago. de 2025, 10:55 UTC

Ganhos

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 de ago. de 2025, 10:53 UTC

Ganhos

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

5 de ago. de 2025, 10:51 UTC

Ganhos

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

Comparação entre Pares

Variação de preço

Pfizer Previsão

Preço-alvo

By TipRanks

4.85% parte superior

Previsão para 12 meses

Média 28.53 USD  4.85%

Máximo 34 USD

Mínimo 24 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Pfizer - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

17 ratings

4

Comprar

12

Manter

1

Vender

Pontuação Técnica

By Trading Central

22.855 / 23.85Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

140 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat